| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Tan X et al. | Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. | 2009 | Kidney Int. | pmid:19759524 |
| Andress DL et al. | Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. | 2008 Jan-Feb | Endocr Pract | pmid:18238737 |
| Mathew S et al. | Vitamin D receptor activators can protect against vascular calcification. | 2008 | J. Am. Soc. Nephrol. | pmid:18448587 |
| Cozzolino M et al. | Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol. | 2008 | Curr Vasc Pharmacol | pmid:18393917 |
| Ross EA et al. | Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. | 2008 | Am. J. Nephrol. | pmid:17914251 |
| Noonan W et al. | Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. | 2008 | Nephrol. Dial. Transplant. | pmid:18644798 |
| Kyritsis I et al. | Combination of sodium thiosulphate, cinacalcet, and paricalcitol in the treatment of calciphylaxis with hyperparathyroidism. | 2008 | Int J Artif Organs | pmid:18825648 |
| Zhang Z et al. | Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. | 2008 | Proc. Natl. Acad. Sci. U.S.A. | pmid:18838678 |
| Weir MR | Is activated vitamin D supplementation renoprotective? | 2008 | Hypertension | pmid:18606899 |
| Alborzi P et al. | Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. | 2008 | Hypertension | pmid:18606901 |
| Cozzolino M and Brancaccio D | Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism. | 2008 | Expert Opin Pharmacother | pmid:18377338 |
| Tan X et al. | Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. | 2008 | J. Am. Soc. Nephrol. | pmid:18525004 |
| Freundlich M et al. | Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. | 2008 | Kidney Int. | pmid:18813285 |
| Shinaberger CS et al. | Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. | 2008 | Clin J Am Soc Nephrol | pmid:18701614 |
| Lopez I et al. | The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. | 2008 | Kidney Int. | pmid:18004298 |
| Fernández Giráldez ED | [Clinical advances in vascular calcification]. | 2008 | Nefrologia | pmid:18847418 |
| Karavalakis E et al. | Paricalcitol treatment and arterial tone in experimental renal insufficiency. | 2008 | Nephron Exp. Nephrol. | pmid:18663335 |
| Faull RJ | Managing bone parameters in dialysis patients: international guideline conflicts. | 2007 May-Jun | Semin Dial | pmid:17555479 |
| Brancaccio D et al. | Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs. | 2007 Jan-Feb | J. Nephrol. | pmid:17347966 |
| Palaparthy R et al. | Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects. | 2007 | Biopharm Drug Dispos | pmid:17173278 |
| Wu-Wong JR et al. | VDR-mediated gene expression patterns in resting human coronary artery smooth muscle cells. | 2007 | J. Cell. Biochem. | pmid:17115413 |
| Mizobuchi M et al. | Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. | 2007 | J. Am. Soc. Nephrol. | pmid:17513326 |
| Huybers S and Bindels RJ | Vascular calcification in chronic kidney disease: new developments in drug therapy. | 2007 | Kidney Int. | pmid:17805315 |
| Lee GH et al. | Impact of kidney bone disease and its management on survival of patients on dialysis. | 2007 | J Ren Nutr | pmid:17198930 |
| Wu-Wong JR et al. | Vitamin D analogs modulate the expression of plasminogen activator inhibitor-1, thrombospondin-1 and thrombomodulin in human aortic smooth muscle cells. | 2007 | J. Vasc. Res. | pmid:17159355 |
| Lazar E et al. | Long-term outcomes of cinacalcet and paricalcitol titration protocol for treatment of secondary hyperparathyroidism. | 2007 | Am. J. Nephrol. | pmid:17429197 |
| Kalantar-Zadeh K | Survival differences between activated injectable vitamin D2 and D3 analogs. | 2007 | Kidney Int. | pmid:17429422 |
| Wu-Wong JR et al. | Elevated phosphorus modulates vitamin D receptor-mediated gene expression in human vascular smooth muscle cells. | 2007 | Am. J. Physiol. Renal Physiol. | pmid:17715259 |
| Hernandez JD et al. | Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol. | 2007 | Nat Clin Pract Nephrol | pmid:17389892 |
| Mansour J et al. | Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism. | 2007 | Nat Clin Pract Nephrol | pmid:17389886 |
| Greenbaum LA et al. | Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. | 2007 | Am. J. Kidney Dis. | pmid:17533024 |
| Andress D | Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. | 2007 | Drugs | pmid:17883284 |
| Brancaccio D et al. | Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies. | 2007 | Drugs | pmid:17883283 |
| Monier-Faugere MC et al. | Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal-parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease. | 2007 | Clin J Am Soc Nephrol | pmid:17942766 |
| Bodyak N et al. | Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. | 2007 | Proc. Natl. Acad. Sci. U.S.A. | pmid:17942703 |
| Joy MS et al. | Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. | 2007 | J Manag Care Pharm | pmid:17605511 |
| Gal-Moscovici A and Sprague SM | Comparative cost-benefit analyses of paricalcitol and calcitriol in stage 4 chronic kidney disease from the perspective of a health plan. | 2007 | Clin Drug Investig | pmid:17217315 |
| Drüeke TB and Fukagawa M | Whole or fragmentary information on parathyroid hormone? | 2007 | Clin J Am Soc Nephrol | pmid:17928465 |
| Fiedler R | Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis. | 2007 | Clin Drug Investig | pmid:18020546 |
| Fryer RM et al. | Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. | 2007 | Nephron Physiol | pmid:17622742 |
| Gordon PL et al. | Relationship between vitamin D and muscle size and strength in patients on hemodialysis. | 2007 | J Ren Nutr | pmid:17971312 |
| Mizobuchi M et al. | Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. | 2007 | Kidney Int. | pmid:17597697 |
| Cardús A et al. | Differential effects of vitamin D analogs on vascular calcification. | 2007 | J. Bone Miner. Res. | pmid:17352647 |
| Repo JM et al. | Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol. | 2007 | Kidney Int. | pmid:17667981 |
| Toledano Mayoral G et al. | [Inappropriate commercial presentation of selected drugs and associated overcost]. | 2006 May-Jun | Farm Hosp | pmid:16999568 |
| Cannella G and Messa P | Therapy of secondary hyperparathyroidism to date: vitamin D analogs, calcimimetics or both? | 2006 Jul-Aug | J. Nephrol. | pmid:17048195 |
| Alagbala AA et al. | Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells. | 2006 | Oncology | pmid:17237623 |
| Nishizawa Y and Shoji T | Does paricalcitol reduce proteinuria in patients with chronic kidney disease? | 2006 | Nat Clin Pract Nephrol | pmid:16932459 |
| Rosery H et al. | Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis. | 2006 | Clin Drug Investig | pmid:17163297 |
| Shalhoub V et al. | Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols. | 2006 | Calcif. Tissue Int. | pmid:17171500 |
Paricalcitol
Paricalcitol is a lipid of Sterol Lipids (ST) class. Paricalcitol is associated with abnormalities such as Vitamin D Deficiency. The involved functions are known as Hypertrophy, Left Ventricular. Paricalcitol often locates in Blood.
Cross Reference
Introduction
To understand associated biological information of Paricalcitol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Paricalcitol?
Paricalcitol is suspected in Vitamin D Deficiency and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
No disease MeSH terms mapped to the current reference collection.
PubChem Associated disorders and diseases
What pathways are associated with Paricalcitol
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Paricalcitol?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Paricalcitol?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Paricalcitol?
There are no associated biomedical information in the current reference collection.
What genes are associated with Paricalcitol?
There are no associated biomedical information in the current reference collection.
What common seen animal models are associated with Paricalcitol?
There are no associated biomedical information in the current reference collection.